PALI-2108 is orally delivered and colon-specific allowing for local activity with low systemic exposure Company on track to commence Phase…
2,300 patients in trial enrolled ahead of schedule12-month follow up period underway, with topline data anticipated in 2H 2025Trial designed…
Eight of 12 evaluable patients (66.7%) had progression-free survival (PFS) ranging from 5 to 11 months At the highest NGC-Cap dose,…
BOSTON, June 11, 2024 (GLOBE NEWSWIRE) -- Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies designed…
NEEDHAM, Mass., June 11, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage…
SAN DIEGO, June 11, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic…
Publication Highlights Activity of the Combination of TRC102 and Temodar (Temozolomide) in Patients who Progressed Following Initial Treatment with Surgical…
REDWOOD CITY, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use…
-- New patent extends patent term for obicetrapib until July 2043 -- NAARDEN, the Netherlands and MIAMI, June 11, 2024 (GLOBE NEWSWIRE)…
SHANGHAI, June 11, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company…